The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial

The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial

Abstract Introduction In 2023, the final PAOLA-1 trial (NCT02477644) survival data were published documenting the benefits of therapy consisting of olaparib plus bevacizumab for patients with advanced ovarian cancer (AOC) as a function of molecular status. In light of these new data, the present stu...

Full description

Bibliographic Details
Main Authors:	Youwen Zhu, Kun Liu, Hui Cao, Hong Zhu
Format:	Article
Language:	English
Published:	BMC 2023-08-01
Series:	Journal of Ovarian Research
Subjects:	Advanced ovarian cancer Olaparib plus bevacizumab BRCA mutation HRD-positive Quality-adjusted life-years
Online Access:	https://doi.org/10.1186/s13048-023-01257-4

Similar Items

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)

The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice
by: S V Khokhlova
Published: (2016-12-01)

Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice
by: Ignacio Romero, et al.
Published: (2024-01-01)

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations
by: Kazuho Nakanishi, et al.
Published: (2023-05-01)

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial
by: Dean A. Fennell, et al.
Published: (2022-10-01)

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway
by: Yasushi Iida, et al.
Published: (2024-02-01)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
by: Domenica Lorusso, et al.
Published: (2022-03-01)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
by: Brigida Anna Maiorano, et al.
Published: (2023-04-01)

BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives
by: Eleonora Molinaro, et al.
Published: (2020-11-01)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report
by: Rosa Montero-Macias, et al.
Published: (2021-04-01)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
by: Hongyu Gong, et al.
Published: (2023-03-01)

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis
by: Yanhui Li
Published: (2023-12-01)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
by: Shinya Yamamoto, et al.
Published: (2023-06-01)

Ovarian cancer molecular stratification and tumour heterogeneity; a necessity and a challenge
by: Stefan eSymeonides, et al.
Published: (2015-10-01)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
by: Yamin Shu, et al.
Published: (2022-08-01)

Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer
by: E Sun Paik, et al.
Published: (2023-06-01)

First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
by: Tomao F, et al.
Published: (2020-07-01)

Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program
by: A. A. Rumyantsev, et al.
Published: (2022-06-01)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
by: Brian T. Burgess, et al.
Published: (2020-02-01)

Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
by: Gilda Magliacane, et al.
Published: (2022-12-01)

PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
by: István Baradács, et al.
Published: (2024-02-01)

Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers
by: Dominik Dannehl, et al.
Published: (2023-07-01)

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
by: Toko Kumeta, et al.
Published: (2019-10-01)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
by: Na Li, et al.
Published: (2021-04-01)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
by: Elisena Franzese, et al.
Published: (2019-11-01)

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer
by: Morgan Bailey, et al.
Published: (2024-03-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer – International considerations amongst upper middle- and high-income countries (UMIC and HIC)
by: Jeffrey C.H. Goh, et al.
Published: (2022-08-01)

Practical aspects of treating relapsed BRCA-associated ovarian cancer
by: A. A. Rumyantse, et al.
Published: (2019-12-01)

Treatment outcomes of patients with BRCA-mutated, recurrent ovarian cancer in University Hospital Center Split
by: Branka Petrić-Miše, et al.
Published: (2022-01-01)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant <i>Brca1</i> Proficient and Deficient Murine Ovarian Cells
by: Michela Chiappa, et al.
Published: (2022-04-01)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
by: Alessandra Anna Prete, et al.
Published: (2022-01-01)

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
by: Angeliki Andrikopoulou, et al.
Published: (2022-12-01)

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
by: Yan Wei, et al.
Published: (2024-03-01)

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
by: Ma J, et al.
Published: (2019-04-01)

The latest first-line treatment options for ovarian cancer: focus on maintenance therapy
by: A. A. Rumyantsev
Published: (2020-12-01)